All In Biotech

Drug Trial Radar · NCT02441283

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Last checked: Nov 20, 2026Latest source record: Sep 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

384

Actual

Start

Jun 22, 2015

Primary completion

Oct 15, 2019

Study completion Oct 15, 2019

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection.

Conditions

  • Hepatitis C

Interventions

  • ABT-493Drug

    ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.

  • ABT-530Drug

    ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Maintained a Sustained Virologic Response (SVR) Out of Those Who Achieved SVR12 in a Prior Study With an ABT-493- and/or ABT-530-containing RegimenTime frame: From the end of treatment in the previous study up to 3 years post-treatment
  2. Percentage of Participants Who Relapsed or Had a New Hepatitis C Virus (HCV) Infection at Any Time up to the Last Follow-up in This Study Among Participants Who Achieved SVR12 in a Prior Study With an ABT-493- and/or ABT-530-containing RegimenTime frame: From the end of treatment in the previous study up to 3 years post-treatment
  3. Number of Participants With Persistence of Resistance-Associated Amino Acid Variants Among Those Experiencing Virologic FailureTime frame: From Day 1 to Month 12

Locations

42 sites in 8 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast /ID# 136725

    Dothan, Alabama

  • Felizarta /ID# 141033

    Bakersfield, California

  • Southern California Res. Ctr. /ID# 141799

    Coronado, California

  • Research & Education, Inc. /ID# 169591

    San Diego, California

  • eStudySite San Diego /ID# 141040

    San Diego, California

  • eStudySite San Diego /ID# 141047

    San Diego, California

  • eStudySite San Diego /ID# 141048

    San Diego, California

  • Midway Immunology and Research /ID# 169477

    Ft. Pierce, Florida

  • Delta Research Partners /ID# 141028

    Bastrop, Louisiana

  • Louisiana Research Ctr. LLC /ID# 141024

    Shreveport, Louisiana

  • Henry Ford Health System /ID# 141039

    Detroit, Michigan

  • Binghamton Gastroenterology /ID# 141026

    Binghamton, New York

  • Carolinas Center for Liver Dis /ID# 155390

    Statesville, North Carolina

  • Northwest Gastroenterology Cli /ID# 141036

    Portland, Oregon

  • Gastro One /ID# 169478

    Germantown, Tennessee

  • Quality Medical Research, PLLC /ID# 141042

    Nashville, Tennessee

  • TX Clinical Research Institute /ID# 141037

    Arlington, Texas

  • Inquest Clinical Research /ID# 141045

    Baytown, Texas

  • TX Liver Inst, Americ Res Corp /ID# 136727

    San Antonio, Texas

  • Bon Secours St. Mary's Hospita /ID# 165106

    Richmond, Virginia

  • St. Vincent's Hospital, Darlinghurst /ID# 155395

    Darlinghurst, New South Wales, Australia

  • St. Vincents Hospital /ID# 155394

    East Lismore, New South Wales, Australia

  • Westmead Hospital /ID# 155392

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital /ID# 155396

    Herston, Queensland, Australia

  • Royal Adelaide Hospital /ID# 155391

    Adelaide, South Australia, Australia

  • Royal Melbourne Hospital /ID# 155393

    Parkville, Victoria, Australia

  • CHU St. Pierre /ID# 155399

    Brussels, Belgium

  • UZ Leuven /ID# 155398

    Leuven, Belgium

  • Cliniques Universitaires Saint Luc /ID# 155397

    Woluwe-Saint-Lambert, Brussels Capital, Belgium

  • University of Calgary /ID# 155400

    Calgary, Alberta, Canada

  • Toronto Liver Centre /ID# 155401

    Toronto, Ontario, Canada

  • Mauss, Schmutz, Hegener, Athma /ID# 155402

    Düsseldorf, Germany

  • Gastroenterologisch-Hepatologi /ID# 169820

    Kiel, Germany

  • Universitätsklinikum Frankfurt /ID# 169817

    Frankfurt am Main, Hesse, Germany

  • Auckland City Hospital /ID# 155403

    Auckland, New Zealand

  • Gastro-Hepato & Geriatric Ctr /ID# 141060

    Ponce, Puerto Rico

  • Klinical Investigations Group /ID# 141059

    San Juan, Puerto Rico

  • Innovative Care P.S.C. /ID# 141061

    San Juan, Puerto Rico

  • King's College Hospital NHS /ID# 155406

    London, United Kingdom

  • St. Mary's Hospital /ID# 155404

    London, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.